tecfideraTecfidera is the trade name for dimethyl fumarate. This drug was formally called BG-12 and is an oral preparation used in treating relapsing-remitting Multiple Sclerosis in adults. Its immunomodulatory and immunosuppression properties make it an ideal choice for patients with Multiple Sclerosis. When used Tecfidera will help in reducing the occurrence of relapses of MS attacks. It will additionally slow down the progression of disability associated with MS.


In achieving its effect, Tecfidera is assumed to inhibit certain cells and molecules of the immune system. These cuts down the rate of inflammation in the central nervous system which causes demyelination of central nervous system. Tecfidera is also thought to have anti-oxidant properties.


Study through clinical trials; show that Tecfidera has the following positive effects on patients with Multiple sclerosis:

  • It markedly reduced relapses in Multiple Sclerosis by up to 53% in most of the people under treatment.

There was a noteworthy reduction of brain lesions associated with MS that were detected by MRI. Gd+ lesions went down by up to 90 percent while T2 Lesions were reduced by up to 85 percent.

Progression of disability was significantly decreased. The EDSS (Expanded Disability Status Scale) showed up to38 percent decrease in the rate of progression.

The general well-being of patients on this drug was remarkably improved after being on the drug for some time.


Tecfidera is administered orally. It can be administered alongside meals.

The early recommended dose is 120 mg two times each day. This is fundamentally a total of 240milligrams each day. This should be continued for seven days.

After the initial week of therapy the dose is adjusted to about 480mg of Tecfidera daily. This is administered as two 240milligram capsules taken orally each day.

The use of this drug is, however, limited to people over 18 years old. Its safety in pregnancy and lactation is not confirmed, and people in these conditions should consult their GP before going into Tecfidera therapy.


Symptoms of using Tecfidera are more pronounced during the first month of treatment. They, however, dissipate with time. The symptom manifestation varies from one patient to another and may include:

  • Stomach upsets with abdominal pain, nausea and diarrhea
  • Flushing
  • Abnormal urinalysis
  • Abnormal hematological tests


Tecfidera is currently only used for relapsing-remitting Multiple Sclerosis. Patients who have used the drug mostly have the following to say about the drug:

  • Easy to use
  • Improved health status with continued use of the drug
  • Better quality of life with MS
One Response
  1. June 2, 2014